Insilico Medicine

A clinical-stage biotech applying generative AI across target discovery, chemistry, and trials, with its own pipeline of AI-designed drug candidates.

Location: Boston, MA

1 model(1 Small molecule, 1 Language model)

Models (1)

Liquid AI / Insilico Medicine

Released March 3, 2026

17.2K—

Small-molecule drug discovery foundation model covering ADMET, retrosynthesis, drug-target activity, and molecular optimization in a 2.6B checkpoint.

Small moleculeLanguage model